Halozyme Therapeutics (HALO) Q1 2024 Earnings
HALO·Reported May 7, 2024·After market close
Halozyme Therapeutics reported Q1 2024 revenue of $195.9M, missed analyst consensus of $199.8M by $3.9M. Diluted EPS came in at $0.79, beat the $0.70 consensus by $0.09.
Revenue
$195.9Mmissed by $3.9M
Consensus: $199.8MDiluted EPS
$0.79beat by $0.09
Consensus: $0.70
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Halozyme Therapeutics's Q1 2024 earnings report.
Halozyme Therapeutics (HALO) reported Q1 2024 earnings on May 7, 2024 after market close.
Halozyme Therapeutics reported revenue of $195.9M and diluted EPS of $0.79 for Q1 2024.
Revenue missed the consensus estimate of $199.8M by $3.9M. EPS beat the consensus estimate of $0.70 by $0.09.
You can read the 10-Q periodic report (0001159036-24-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.